Proteomic diagnosis

F. Vandenesch, PU-PH

As part of the Idbioriv RHU (identification, resistance and virulence by mass spectrometry), a cohort of bacteremic patients from 19 care dpt of the Hospices Civils de Lyon has been launched in march 2024 and should recruit patients until May 2026. The primary objective is to validate the performance of the IDBIORIV method in identifying and predicting the antibiotic susceptibility profile (AST) in patients with a first positive blood culture in a real clinical situation, in comparison with standard of care.

The secondary objectives are focused on S. aureus bacteremia (SAB), for which around 200 patients should be recruited:

(i) to assess the value of targeted proteomic quantification of 41 virulence factors in the severity of SAB, and

(ii) to provide a descriptive characterization of the humoral (including search for anti-cytokine antibodies), cellular and transcriptomic immunological profile of patients with SAB (collab with S. Assant, CARVI team).